Puma Biotechnology Inc  

(Public, NASDAQ:PBYI)   Watch this stock  
Find more results for PBYI
105.50
+2.35 (2.28%)
Nov 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 102.35 - 106.35
52 week 28.35 - 136.90
Open 102.35
Vol / Avg. 0.00/838,618.00
Mkt cap 3.96B
P/E     -
Div/yield     -
EPS -8.19
Shares 37.53M
Beta 0.85
Inst. own 100%
Nov 15, 2017
Puma Biotechnology Inc at Stifel Healthcare Conference
Nov 9, 2017
Q3 2017 Puma Biotechnology Inc Earnings Call - Webcast
Nov 9, 2017
Q3 2017 Puma Biotechnology Inc Earnings Release
Nov 7, 2017
Puma Biotechnology Inc at Credit Suisse Healthcare Conference - Webcast
Sep 26, 2017
Puma Biotechnology Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 6, 2017
Puma Biotechnology Inc at Citi Biotech Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -1270.04% -
Operating margin -1274.31% -
EBITD margin - -
Return on average assets -174.56% -112.06%
Return on average equity -310.69% -132.75%
Employees 308 -
CDP Score - -

Address

10880 Wilshire Blvd Ste 2150
LOS ANGELES, CA 90024-4106
United States - Map
+1-424-2486500 (Phone)
+1-424-2486501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. Its initial focus is on the development of neratinib as an oral treatment of patients with HER2 positive metastatic breast cancer. It focuses on developing neratinib as an intravenously administered agent. The intravenous version of neratinib resulted in exposure levels of neratinib in pre-clinical models. Its product candidate, PB357, is an orally administered agent that is an irreversible TKI that blocks signal transduction through the epidermal growth factor receptors.

Officers and directors

Alan H. Auerbach Chairman of the Board, President, Chief Executive Officer
Age: 47
Bio & Compensation  - Reuters
Charles R. Eyler Senior Vice President - Finance and Administration, Treasurer
Age: 69
Bio & Compensation  - Reuters
Richard P. Bryce Chief Scientific Officer, Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Steven Lo Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Jay M. Moyes Independent Director
Age: 63
Bio & Compensation  - Reuters
Adrian M Senderowicz Independent Director
Age: 53
Bio & Compensation  - Reuters
Troy E. Wilson Ph.D. J.D. Independent Director
Age: 48
Bio & Compensation  - Reuters
Frank E. Zavrl Independent Director
Age: 51
Bio & Compensation  - Reuters